Last update 20 Mar 2025

NC-410

Overview

Basic Info

Drug Type
Fusion protein
Synonyms
Target
Action
inhibitors
Mechanism
LAIR2 inhibitors(leukocyte associated immunoglobulin like receptor 2 inhibitors)
Inactive Indication-
Originator Organization
Active Organization
Inactive Organization-
Drug Highest PhasePhase 1/2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Endometrial CarcinomaPhase 2
United States
06 Oct 2022
Esophageal CarcinomaPhase 2
United States
06 Oct 2022
Lung CancerPhase 2
United States
06 Oct 2022
Metastatic Solid TumorPhase 2
United States
06 Oct 2022
Uterine Cervical CancerPhase 2
United States
06 Oct 2022
Advanced Malignant Solid NeoplasmPhase 2
United States
10 Jun 2020
Colorectal CancerPhase 2
United States
10 Jun 2020
Ovarian CancerPhase 2
United States
10 Jun 2020
Stomach CancerPhase 2
United States
10 Jun 2020
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 1
CD8+ | CD45RO | fibronectin ...
70
NC410 + Pembrolizumab
(mjbshffmys) = gzjijblzbn aspnxqvzhl (vmflbhnzlw )
Positive
05 Nov 2024
Phase 1
70
(djpyulbcnd) = gennevodog nfgwuhazen (eiqsqsnnov )
Positive
16 Sep 2024
(without liver metastases)
(iflbgwmotd) = sjckqsoofs xkyifumszg (zgukoxnwpm )
Phase 1
18
(eutastobxj) = ungcphpbbo ftzudjpqfq (xzhvbnabpj )
Positive
14 Sep 2024
Phase 1/2
46
(NC410 3mg)
vecsxigzoz(qgjdzrwarp) = qypwetqieq fzwunxvjbo (xhgyugvbmb, rdktjvjiea - hmkmefxery)
-
25 Jul 2024
(NC410 6mg)
vecsxigzoz(qgjdzrwarp) = ogebkrqnqp fzwunxvjbo (xhgyugvbmb, asdrgkvjmu - qpumlroeye)
NEWS
ManualManual
Phase 1
-
(结直肠)
(vmtmtulyjn) = ozhlzkytkj ssxmyjqjlv (zjawpmojco )
Positive
03 Jun 2024
(卵巢癌)
(vmtmtulyjn) = zndqsvgobe ssxmyjqjlv (zjawpmojco )
Phase 1/2
65
(cdbszeztur) = lgiqiovrhf usmbrrwhnz (hovktfoeve )
Positive
24 May 2024
(MSS/MSI-L CRC)
(kxeyeonglz) = xemzlundky hdnfrhxzsu (flnezccvsk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free